


Edited by W. R. Külpmann

 WILEY-
BLACKWELL

Clinical Toxicological Analysis

Procedures, Results, Interpretation

Volume 1



Contents

Foreword	V
Preface	XIX
List of Contributors	XXI
Disclaimer	XXV

Volume 1

1	Introduction	1
	<i>W.R. Külpmann</i>	
	References	3
2	Requirements for Toxicological Analyses	5
	<i>F. Degel</i>	
2.1	General Aspects	5
2.2	Devices	5
2.3	Rooms and Facilities	5
2.4	Management and Technical Requirements	7
2.5	Chemicals and Reagents	8
2.6	Personnel	8
	References	8
3	Materials for Investigation	11
	<i>H.J. Gibitz and F. Pluisch</i>	
3.1	Introduction	11
3.2	Judicial Preconditions for Taking and Surrendering Materials for Investigation	11
3.2.1	The Contract on Medical Treatment	12
3.2.2	Patient's Consent	12
3.2.3	Suicidal Patients	13
3.2.4	Surrender of Materials for Investigation	14
3.3	Containers for Sampling and Storage	15

3.4	Kind of Materials	15
3.4.1	Urine	16
3.4.2	Blood, Plasma, and Serum	17
3.4.3	Stomach Contents	18
3.4.4	Other Materials	18
3.5	Identification of Materials	19
3.6	Request Form	19
3.7	Transport of Materials	19
3.8	Evaluation of Materials	20
3.8.1	Urine	21
3.8.2	Blood	21
3.8.3	Stomach Contents	21
3.8.4	Expired Air	23
3.9	Storage of Materials	23
3.10	Sampling and Storage of Materials for Forensic Investigation	23
	References	24
4	Methods for Clinical Toxicological Analysis	25
4.1	Immunoassays	25
	<i>W.R. Külpmann and D. Hannak</i>	
4.1.1	Introduction	25
4.1.2	Selection of Materials for Investigation	26
4.1.3	Detection Limit and Cutoff Concentration	28
4.1.4	Maximal and Practical Sensitivity	28
4.2	Thin-Layer Chromatography	29
	<i>F. Degel</i>	
4.2.1	Introduction	29
4.2.2	Toxicological Analyses by Thin-Layer Chromatography	30
4.2.3	Perspectives and Limitations	31
4.3	High-Performance Liquid Chromatography	32
	<i>H. Käferstein</i>	
4.3.1	Introduction	32
4.3.2	Packing Materials and Separation Techniques	32
4.3.3	Detection	33
4.3.4	Conclusion	34
4.4	Gas Chromatography	35
	<i>H.H. Maurer</i>	
4.4.1	Injection	35
4.4.2	Chromatographic Separation and Detection	36
4.4.3	Conclusion	37
4.5	Gas Chromatography–Mass Spectrometry	38
	<i>H.H. Maurer</i>	
4.5.1	Outline	38
4.5.2	Instrumentation	38
4.5.3	Full Scan Mode and Selected Ion Monitoring	39

4.6	Headspace Gas Chromatography	40
	<i>F. Degel</i>	
4.6.1	Introduction	40
4.6.2	Outline	40
4.6.3	Sampling	40
4.6.4	Sample Preparation	41
4.6.5	Sample Introduction	41
4.6.6	Calibration	42
4.6.7	Practicability	43
4.7	Liquid Chromatography–Mass Spectrometry	43
	<i>H.H. Maurer</i>	
4.8	Electrochemical Methods	46
	<i>F. Pragst</i>	
4.8.1	Introduction	46
4.8.2	Potentiometry	46
4.8.3	Inverse Voltammetry	49
4.8.4	Electrochemical Detection for HPLC	50
4.9	Capillary Electrophoresis	54
	<i>H. König</i>	
	References	55
5	Practicability of Clinical Toxicological Analyses	59
	<i>H.J. Gibitz</i>	
5.1	Introduction	59
5.2	Aspects of Practicability	59
5.2.1	Time Periods	59
5.2.2	Recording of Time	61
5.3	Personnel Cost	61
5.4	Conclusion	62
	References	62
6	Quality Assurance	63
6.1	Quantitative Measurements	63
	<i>W.R. Külpmann</i>	
6.1.1	Introduction	63
6.1.2	Internal Quality Assurance	63
6.1.3	External Quality Assessment	65
6.1.4	Perspectives	66
6.2	Qualitative Examinations	66
	<i>L. von Meyer and M. Geldmacher-von Mallinckrodt</i>	
6.2.1	Types of Qualitative Analyses	66
6.2.2	Relevant International Standards	66
6.2.3	Differences Concerning Terms and Definitions	68
6.2.4	Quality Assurance of Qualitative Examinations According to MEQUALAN	68

6.2.5	Uncertainty and Unreliability	71
6.2.6	Quality Assurance: A Practical Approach	73
	<i>W.R. Külpmann</i>	
	References	75
7	Assessment of Analytical Results	77
	<i>W.R. Külpmann, M. Geldmacher-von Mallinckrodt, and J. Hallbach</i>	
7.1	Introduction	77
7.2	Technical Level: Analytical Assessment	77
7.3	Biological Level: Plausibility Check	78
7.4	Nosological Level	79
	References	79
8	The Analytical Toxicological Report	81
	<i>J. Hallbach, M. Geldmacher-von Mallinckrodt, and W.R. Külpmann</i>	
8.1	Introduction	81
8.2	The Analytical Toxicological Report	81
	References	87
9	Medical Interpretation	89
	<i>J. Hallbach, N. Felgenhauer, M. Geldmacher-von Mallinckrodt, and H.H. Maurer</i>	
9.1	Overview	89
9.2	Differential Diagnosis	90
9.3	Poison Information Center	90
9.4	Interpretation of Blood, Plasma, or Serum Concentrations	90
9.5	Conclusion	91
	References	92
10	Forensic Aspects	93
	<i>W.R. Külpmann</i>	
10.1	Overview	93
	References	94
11	Strategy of Clinical Toxicological Investigations	95
	<i>J. Hallbach, W.R. Külpmann, H.H. Maurer, F. Pragst, and N. Felgenhauer</i>	
11.1	Epidemiology of Poisoning	95
11.2	Diagnosis of Poisoning	96
11.3	Investigation Request	100
11.4	Clinical Toxicological Requirements	102
11.5	Documentation	105
	References	105
12	Screening Procedures for “General Unknown” Analysis	107
	<i>F. Pragst, H.H. Maurer, J. Hallbach, W.R. Külpmann, U. Staerk, F. Degel, and M. Lappenberg-Pelzer</i>	

12.1	High-Performance Liquid Chromatography with Photodiode Array Detector	108
	<i>F. Pragst</i>	
12.1.1	Sample Preparation	108
12.1.2	Chromatographic Conditions	120
12.1.3	HPLC–DAD Spectra Libraries	126
12.1.4	Identification of Metabolites	131
12.1.5	Estimation of Concentration	135
12.1.6	Application Examples	138
12.1.7	Practicability	147
12.1.8	Mechanized High-Performance Liquid Chromatography	148
	<i>J. Hallbach</i>	
12.2	Gas Chromatography	151
	<i>H. H. Maurer</i>	
12.3	Gas Chromatography–Mass Spectrometry	152
	<i>H.H. Maurer</i>	
12.3.1	Instruments and Settings	152
12.3.2	Procedure and Data Evaluation	153
12.3.3	Quality Assurance of Screening Procedures	154
12.3.4	Screening for Basic and Neutral Drugs and Poisons in Urine	156
12.3.5	Screening for Acidic Drugs and Poisons in Urine	159
12.3.6	Identification and Determination of Drugs and Poisons in Plasma	161
12.3.7	Solid-Phase Microextraction	163
	<i>W.R. Külpmann and U. Staerk</i>	
12.4	Gas Chromatographic Headspace Analysis	165
	<i>F. Degel</i>	
12.4.1	Introduction	165
12.4.2	Screening Procedure	167
12.5	Color Test: Tetrabromophenolphthalein Ethyl Ester	175
	<i>M. Lappenberg-Pelzer</i>	
12.5.1	Introduction	175
12.5.2	Procedure	176
12.5.3	Medical Assessment and Clinical Interpretation	181
	References	182
13	Nonopioid Analgesics and Antirheumatics	189
	<i>H. König and J. Hallbach</i>	
13.1	Detection of Nonopioid Analgesics and Antirheumatics in Serum and Urine	189
13.1.1	Screening by High-Performance Liquid Chromatography	190
13.1.2	Medical Assessment and Clinical Interpretation	194
13.1.3	Screening by Gas Chromatography	195
13.1.4	Medical Assessment and Clinical Interpretation	198
13.2	Diclofenac	199
13.2.1	High-Performance Liquid Chromatography	199

13.2.2	Gas Chromatography	199
13.2.3	Medical Assessment and Clinical Interpretation	199
13.3	Ibuprofen	200
13.3.1	High-Performance Liquid Chromatography	200
13.3.2	Gas Chromatography	201
13.3.3	Medical Assessment and Clinical Interpretation	201
13.4	Metamizole (Dipyrone)	202
13.4.1	High-Performance Liquid Chromatography	202
13.4.2	Gas Chromatography	202
13.4.3	Medical Assessment and Clinical Interpretation	202
13.5	Paracetamol (Acetaminophen)	203
13.5.1	Immunoassay	203
13.5.2	High-Performance Liquid Chromatography	204
13.5.3	Gas Chromatography	204
13.5.4	Medical Assessment and Clinical Interpretation	204
13.6	Phenazone (Antipyrine)	207
13.6.1	High-Performance Liquid Chromatography	207
13.6.2	Gas Chromatography	207
13.6.3	Medical Assessment and Clinical Interpretation	207
13.7	Salicylates	209
13.7.1	Photometry	209
13.7.2	Immunoassay	211
13.7.3	High-Performance Liquid Chromatography	211
13.7.4	Gas Chromatography	212
13.7.5	Medical Assessment and Clinical Interpretation	212
	References	214

14 Analgesics: Opiates and Opioids 215

H. Käferstein

14.1	Group Assays	216
14.1.1	Immunoassay	216
14.1.2	High-Performance Liquid Chromatography	216
14.1.3	Gas Chromatography	216
14.1.4	Medical Assessment and Clinical Interpretation	216
14.2	Buprenorphine	216
	<i>W.R. Külpmann</i>	
14.2.1	Immunoassay	216
14.2.2	High-Performance Liquid Chromatography	217
14.2.3	Gas Chromatography – Mass Spectrometry	217
14.2.4	Medical Assessment and Clinical Interpretation	217
14.3	Dextropropoxyphene	218
	<i>H. Käferstein</i>	
14.3.1	Immunoassay	219
14.3.2	High-Performance Liquid Chromatography	219
14.3.3	Gas Chromatography – Mass Spectrometry	221

14.3.4	Medical Assessment and Clinical Interpretation	221
14.4	Fentanyl	222
	<i>G. Sticht, H. Käferstein, and L. von Meyer</i>	
14.4.1	Immunoassay	223
14.4.2	High-Performance Liquid Chromatography	224
14.4.3	Gas Chromatography – Mass Spectrometry	224
14.4.4	Medical Assessment and Clinical Interpretation	227
14.5	Meperidine (Pethidine)	228
	<i>H. König</i>	
14.5.1	Immunoassay	228
14.5.2	Chromatography	229
14.5.3	Medical Assessment and Clinical Interpretation	229
14.6	Methadone	230
	<i>H. Käferstein and A. Schmoldt</i>	
14.6.1	Immunoassay	231
14.6.2	High-Performance Liquid Chromatography: Total Methadone	231
14.6.3	High-Performance Liquid Chromatography: L- and D-Methadone	234
14.6.4	Gas Chromatography – Mass Spectrometry	236
14.6.5	Medical Assessment and Clinical Interpretation	238
14.7	Morphine and Morphine Derivatives	240
	<i>H. Käferstein and G. Sticht</i>	
14.7.1	Immunoassay	243
14.7.2	High-Performance Liquid Chromatography	244
14.7.3	Gas Chromatography – Mass Spectrometry	244
14.7.4	Medical Assessment and Clinical Interpretation	247
14.8	Oxycodone	249
	<i>F. Degel</i>	
14.8.1	Immunoassay	250
14.8.2	Chromatography	250
14.8.3	Medical Assessment and Clinical Interpretation	251
14.9	Pentazocine	252
	<i>T. Binscheck</i>	
14.9.1	High-Performance Liquid Chromatography	253
14.9.2	Gas Chromatography – Mass Spectrometry	255
14.9.3	Medical Assessment and Clinical Interpretation	257
14.10	Tilidine	257
	<i>T. Binscheck</i>	
14.10.1	High-Performance Liquid Chromatography	258
14.10.2	Gas Chromatography – Mass Spectrometry	259
14.10.3	Medical Assessment and Clinical Interpretation	261
14.11	Tramadol	262
	<i>J. Hallbach and H. Käferstein</i>	
14.11.1	Immunoassay	262
14.11.2	Chromatography–Mass Spectrometry	262

- 14.11.3 Medical Assessment and Clinical Interpretation 263
References 266

- 15 Antidysrhythmic Agents 271**
H. König and A. Schmoldt
- 15.1 Immunoassay 272
- 15.2 High-Performance Liquid Chromatography 273
- 15.3 Gas Chromatography 274
- 15.4 Medical Assessment and Clinical Interpretation 275
References 285

- 16 Anticonvulsants 287**
D. Hannak
- 16.1 Immunoassay 288
W.R. Külpmann
- 16.2 High-Performance Liquid Chromatography 289
D. Hannak
- 16.3 Gas Chromatography–Mass Spectrometry 291
J. Hallbach
- 16.4 Medical Assessment and Clinical Interpretation 294
D. Hannak
References 300

- 17 Anticoagulants 301**
L. von Meyer and M. Geldmacher-von Mallinckrodt
- 17.1 Coumarin Derivatives Used in Therapy 302
- 17.1.1 General Screening Methods 302
- 17.1.2 High-Performance Liquid Chromatography 303
- 17.1.3 Medical Assessment and Clinical Interpretation 306
- 17.2 Rodenticide Coumarin Derivatives 309
- 17.2.1 General Screening Methods 309
- 17.2.2 High-Performance Liquid Chromatography 309
- 17.2.3 Medical Assessment and Clinical Interpretation 310
References 311

- 18 Bronchodilators 313**
W.R. Külpmann
- 18.1 Group Assay 313
- 18.2 Caffeine 313
- 18.2.1 Immunoassay 313
- 18.2.2 High-Performance Liquid Chromatography 313
- 18.2.3 Gas Chromatography – Mass Spectrometry 314
- 18.2.4 Medical Assessment and Clinical Interpretation 314
- 18.3 Theophylline 315
- 18.3.1 Immunoassay 315

- 18.3.2 High-Performance Liquid Chromatography 315
- 18.3.3 Gas Chromatography – Mass Spectrometry 315
- 18.3.4 Medical Assessment and Clinical Interpretation 315
- References 316

19 Calcium Channel Blockers 317

J. Hallbach and A. Schmoldt

- 19.1 Nifedipine 317
 - 19.1.1 Introduction 317
 - 19.1.2 High-Performance Liquid Chromatography 318
 - 19.1.3 Medical Assessment and Clinical Interpretation 318
- 19.2 Verapamil 320
 - 19.2.1 Introduction 320
 - 19.2.2 High-Performance Liquid Chromatography 320
 - 19.2.3 Gas Chromatography 322
 - 19.2.4 Medical Assessment and Clinical Interpretation 324
 - References 325

20 Cardiac Glycosides 327

J. Hallbach

- 20.1 Digitoxin 327
 - 20.1.1 Immunoassay 328
 - 20.1.2 Medical Assessment and Clinical Interpretation 329
 - 20.1.3 Annotations 331
- 20.2 Digoxin 331
 - 20.2.1 Immunoassay 332
 - 20.2.2 Medical Assessment and Clinical Interpretation 333
 - 20.2.3 Annotations 336
 - References 336

21 Hypnotics: Barbiturates 339

W.R. Külpmann and A. Schmoldt

- 21.1 Detection of Barbiturates 339
 - 21.1.1 Immunoassay 339
 - 21.1.2 High-Performance Liquid Chromatography 340
 - 21.1.3 Gas Chromatography 340
 - 21.1.4 Medical Assessment and Clinical Interpretation 340
- 21.2 Methohexital 340
 - A. Schmoldt and W.R. Külpmann*
 - 21.2.1 High-Performance Liquid Chromatography 340
 - 21.2.2 Gas Chromatography 343
 - 21.2.3 Medical Assessment and Clinical Interpretation 345
- 21.3 Phenobarbital 345
 - W.R. Külpmann*
 - 21.3.1 Immunoassay 345

21.3.2	High-Performance Liquid Chromatography	346
21.3.3	Gas Chromatography – Mass Spectrometry	347
21.3.4	Medical Assessment and Clinical Interpretation	347
21.4	Thiopental	347
	<i>W.R. Külpmann</i>	
21.4.1	High-Performance Liquid Chromatography	347
21.4.2	Gas Chromatography	348
21.4.3	Medical Assessment and Clinical Interpretation	350
	References	350
22	Hypnotics and Sedatives: Benzodiazepines	351
	<i>L. von Meyer, A. Schmoldt, and W.R. Külpmann</i>	
22.1	Immunoassay	351
22.2	High-Performance Liquid Chromatography	352
22.3	Gas Chromatography	356
22.4	Medical Assessment and Clinical Interpretation	356
	References	364
23	Hypnotics and Sedatives (Except for Barbiturates and Benzodiazepines)	367
	<i>H. König and H. Käferstein</i>	
23.1	Immunoassay	367
23.2	High-Performance Liquid Chromatography	368
23.3	Gas Chromatography	372
23.4	Ion-Selective Electrodes	376
	<i>F. Pragst</i>	
23.5	Photometry (Color Test)	377
	<i>H. J. Gibitz</i>	
23.6	Medical Assessment and Clinical Interpretation	380
	References	391
24	Neuroleptic Drugs and Antidepressants	393
24.1	Group Assays	393
24.1.1	Immunoassay	393
	<i>F. Degel, W. Steimer, and T. Grobosch</i>	
24.1.2	Color Test	394
	<i>M. Geldmacher-von Mallinckrodt</i>	
24.2	High-Performance Liquid Chromatography	396
	<i>H.-J. Birkhahn and D. Lampe</i>	
24.2.1	Outline	396
24.2.2	Procedure	397
24.3	High-Performance Liquid Chromatography (Dedicated Systems)	400
	<i>W. Steimer</i>	
24.3.1	Introduction	400

24.3.2	Outline	400
24.3.3	Procedure	401
24.4	Gas Chromatography	404
	<i>H.-J. Birkhahn and D. Lampe</i>	
24.4.1	Outline	404
24.4.2	Procedure	404
24.5	Gas Chromatography–Mass Spectrometry	407
	<i>U. Demme</i>	
24.5.1	Introduction	407
24.5.2	Outline	410
24.5.3	Procedure	411
24.5.4	Detailed Analytical Information on Some Relevant Drugs	414
24.6	High-Performance Thin-Layer Chromatography	422
	<i>U. Demme</i>	
24.6.1	Introduction	422
24.6.2	Outline	423
24.6.3	Procedure	424
24.7	High-Performance Liquid Chromatography–Mass Spectrometry	430
	<i>T. Grobosch</i>	
24.7.1	Outline	430
24.7.2	Procedure	430
24.8	Medical Assessment and Clinical Interpretation	432
	<i>F. Degel</i>	
	References	453

Volume 2

25	β-Receptor Blocking Drugs	455
26	Drugs of Abuse	463
27	Solvents and Inhalants	511
28	Pesticides	559
29	Antidiabetics: Proinsulin, Insulin, C-Peptide, and Oral Antidiabetics	613
30	Dyshemoglobins	623
31	Various Drugs and Toxic Agents	635
32	Chemical Warfare Agents	679

33	Biochemical Investigations in Toxicology	745
34	Therapeutic Drug Monitoring	775
35	Poisonous Plants	785
36	Poisonous Mushrooms	809
37	Venomous and Poisonous Animals	825
	Appendix A Abbreviations	835
	Appendix B Therapeutic and Toxic Concentrations of Drugs and Xenobiotics in Plasma or Serum	841
	Appendix C Biological Tolerance Values at the Workplace (BAT Values)	853
	Appendix D Antidotes	857
	Appendix E Poison Information Centers	861
	Appendix F List of Narcotic Drugs According to German Law	867
	Index	877